Add to Quick Collection All 2 Results
| Title | Author/Creator | Date | Full Text | Reviewed | |
|---|---|---|---|---|---|
| Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy | Hughes, Timothy P.; Branford, Susan; Cooney, Julian; Leahy, Michael F.; Rowlings, Philip... More | 2008 | — | ||
| Juxtamembrane mutant V560GKit is more sensitive to Imatinib (ST1571) compared with wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant | Frost, Michelle J.; Ferrao, Petranel T.; Hughes, Timothy P.; Ashman, Leonie K. | 2002 | — |